135 related articles for article (PubMed ID: 2395811)
1. Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
Tyndale RF; Gonzalez FJ; Hardwick JP; Kalow W; Inaba T
Pharmacol Toxicol; 1990 Jul; 67(1):14-8. PubMed ID: 2395811
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
4. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
5. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
Brøsen K; Zeugin T; Meyer UA
Clin Pharmacol Ther; 1991 Jun; 49(6):609-17. PubMed ID: 2060250
[TBL] [Abstract][Full Text] [Related]
6. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
7. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
Haefeli WE; Bargetzi MJ; Follath F; Meyer UA
J Cardiovasc Pharmacol; 1990 May; 15(5):776-9. PubMed ID: 1692938
[TBL] [Abstract][Full Text] [Related]
8. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
Pressacco J; Muller R; Kalow W
Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
[TBL] [Abstract][Full Text] [Related]
9. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
Tyndale RF; Kalow W; Inaba T
Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
[TBL] [Abstract][Full Text] [Related]
10. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
Ebner T; Eichelbaum M
Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
[TBL] [Abstract][Full Text] [Related]
11. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
Lennard MS
Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
[TBL] [Abstract][Full Text] [Related]
13. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
Tyndale RF; Inaba T; Kalow W
Drug Metab Dispos; 1989; 17(3):334-40. PubMed ID: 2568917
[TBL] [Abstract][Full Text] [Related]
14. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
Inaba T; Tyndale RE; Mahon WA
Br J Clin Pharmacol; 1986 Aug; 22(2):199-200. PubMed ID: 3756068
[No Abstract] [Full Text] [Related]
15. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
Brosen K
Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
[TBL] [Abstract][Full Text] [Related]
16. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.
Otton SV; Inaba T; Mahon WA; Kalow W
Can J Physiol Pharmacol; 1982 Jan; 60(1):102-5. PubMed ID: 7066751
[TBL] [Abstract][Full Text] [Related]
17. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
Küpfer A; Al-Dabbagh SG; Ritchie JC; Idle JR; Smith RL
Biochem Pharmacol; 1982 Oct; 31(20):3193-9. PubMed ID: 7150348
[TBL] [Abstract][Full Text] [Related]
18. Polymorphic oxidation of debrisoquine and sparteine.
Eichelbaum M
Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
[No Abstract] [Full Text] [Related]
19. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
Fonne-Pfister R; Meyer UA
Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
[TBL] [Abstract][Full Text] [Related]
20. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
Ho JW; Moody DE
Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]